Latest News

Latest News

Psychedelic Medicine Commercialization: Altered Perceptions

Psychedelic Medicine Commercialization: Altered Perceptions

Lilly’s acquisition of AtaiBeckley validates the therapeutic and economic promise of rapid-acting neuroplastogens. It also raises a harder question: can commercial teams redesign the beliefs surrounding these medicines as effectively as scientists are redesigning the...

read more
Safety, Toxicology, and Risk Assessment of Essential Oils

Safety, Toxicology, and Risk Assessment of Essential Oils

Essential oils are complex mixtures of volatile phytochemicals that have long been incorporated into traditional medicine, personal care products, aromatherapy, and topical therapeutic formulations. Their diverse biological activities—including antimicrobial,...

read more
Weekly News Roundup | 27 July 2026

Weekly News Roundup | 27 July 2026

Life science news 27 July 2026: GSK wins its first lung cancer approval with a selective ROS1 inhibitor, Lilly's triple agonist retatrutide delivers up to 22.6 per cent weight loss in two pivotal trials, and the MHRA clears what it calls the world's first lower-carbon...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Paediatric Trials: Why Children Remain Therapeutic Orphans

Paediatric Trials: Why Children Remain Therapeutic Orphans

Children have long been described as therapeutic orphans. It is a term first used by the American paediatrician Harry Shirkey of the Children’s Hospital in Birmingham, Alabama, at a 1963 conference and formally published in 1968. Despite more than five decades of...

read more
Global Nursing Shortage: The Life Sciences Risk

Global Nursing Shortage: The Life Sciences Risk

For the life sciences sector, the global nursing shortage is not a background public health concern. It is a clinical trial staffing problem, a pharmaceutical market access problem, and a real-world evidence problem. The WHO's 2025 State of the World's Nursing report...

read more
Why Clinical Trial Diversity Remains a Problem

Why Clinical Trial Diversity Remains a Problem

For decades, clinical trials have failed to adequately represent the patients who will ultimately use the medicines and treatments being tested. Gaps in enrolment across race, ethnicity, sex, age, and socioeconomic background have created an incomplete evidence base,...

read more
Weekly News Roundup | 4 May 2026

Weekly News Roundup | 4 May 2026

Life science news 4 May 2026: Eli Lilly's record $19.8 billion quarterly earnings, the FDA's real-time clinical trial revolution and a landmark week for UK regulatory reform define a momentous seven days for global life science. Eli Lilly reported worldwide revenue of...

read more
The Gap Between Precision Medicine and Clinical Reality

The Gap Between Precision Medicine and Clinical Reality

Precision medicine is no longer a futuristic concept. Genomic panels, pharmacogenomic testing, advanced biomarker analysis, and individualized risk stratification tools are all available today. Yet for the vast majority of patients walking into a primary care office,...

read more
Clinical Trials Roundup | 1 May 2026

Clinical Trials Roundup | 1 May 2026

Etavopivat delivers Phase 3 success in sickle cell disease, satralizumab becomes the first positive Phase 3 result in MOGAD, AstraZeneca completes its triple-positive COPD biologic programme, and a busy week for paediatric medicine brings new approvals and data in...

read more
Longevity Biotech: Separating the Science from the Hype

Longevity Biotech: Separating the Science from the Hype

The Billion-Dollar Race to Slow Ageing Billions of dollars are pouring into the idea that ageing is a disease we can treat. The longevity biotech sector attracted $8.49 billion in private investment across 325 deals in 2024, according to Longevity.Technology's Annual...

read more
Report Finds Seven in Ten Leaders Bullied by Their Teams

Report Finds Seven in Ten Leaders Bullied by Their Teams

Healthcare organisations invest significantly in psychosocial risk frameworks, governance structures and leadership development. Yet a new international study highlights a type of organisational risk that most of those frameworks are not designed to detect. It is a...

read more
Paediatric Trials: Why Children Remain Therapeutic Orphans

Paediatric Trials: Why Children Remain Therapeutic Orphans

Children have long been described as therapeutic orphans. It is a term first used by the American paediatrician Harry Shirkey of the Children’s Hospital in Birmingham, Alabama, at a 1963 conference and formally published in 1968. Despite more than five decades of...

read more
Global Nursing Shortage: The Life Sciences Risk

Global Nursing Shortage: The Life Sciences Risk

For the life sciences sector, the global nursing shortage is not a background public health concern. It is a clinical trial staffing problem, a pharmaceutical market access problem, and a real-world evidence problem. The WHO's 2025 State of the World's Nursing report...

read more
Why Clinical Trial Diversity Remains a Problem

Why Clinical Trial Diversity Remains a Problem

For decades, clinical trials have failed to adequately represent the patients who will ultimately use the medicines and treatments being tested. Gaps in enrolment across race, ethnicity, sex, age, and socioeconomic background have created an incomplete evidence base,...

read more
Weekly News Roundup | 4 May 2026

Weekly News Roundup | 4 May 2026

Life science news 4 May 2026: Eli Lilly's record $19.8 billion quarterly earnings, the FDA's real-time clinical trial revolution and a landmark week for UK regulatory reform define a momentous seven days for global life science. Eli Lilly reported worldwide revenue of...

read more
The Gap Between Precision Medicine and Clinical Reality

The Gap Between Precision Medicine and Clinical Reality

Precision medicine is no longer a futuristic concept. Genomic panels, pharmacogenomic testing, advanced biomarker analysis, and individualized risk stratification tools are all available today. Yet for the vast majority of patients walking into a primary care office,...

read more
Clinical Trials Roundup | 1 May 2026

Clinical Trials Roundup | 1 May 2026

Etavopivat delivers Phase 3 success in sickle cell disease, satralizumab becomes the first positive Phase 3 result in MOGAD, AstraZeneca completes its triple-positive COPD biologic programme, and a busy week for paediatric medicine brings new approvals and data in...

read more
Longevity Biotech: Separating the Science from the Hype

Longevity Biotech: Separating the Science from the Hype

The Billion-Dollar Race to Slow Ageing Billions of dollars are pouring into the idea that ageing is a disease we can treat. The longevity biotech sector attracted $8.49 billion in private investment across 325 deals in 2024, according to Longevity.Technology's Annual...

read more
Report Finds Seven in Ten Leaders Bullied by Their Teams

Report Finds Seven in Ten Leaders Bullied by Their Teams

Healthcare organisations invest significantly in psychosocial risk frameworks, governance structures and leadership development. Yet a new international study highlights a type of organisational risk that most of those frameworks are not designed to detect. It is a...

read more

Featured Articles

FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Pipette dispensing into lab vials with glowing DNA helix and genetic sequence data for Life Science Daily News

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare professionals, communications specialists and industry professionals should be able to publish their own work directly to a specialist audience,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Trump FDA Drug Approvals: Global Impact

Trump FDA Drug Approvals: Global Impact

Trump FDA Drug Approvals: How US Regulatory Upheaval Is Reshaping the Global Pharmaceutical Industry The United States Food and Drug Administration has long been regarded as the gold standard of drug regulation. When a medicine receives FDA approval, it carries a...

read more
Most Supplement Companies Skip the RCT

Most Supplement Companies Skip the RCT

Most Supplement Companies Skip the RCT. Here’s Why the Few That Don’t Often Get It Wrong The industry’s uncomfortable truth The global dietary supplement market is worth hundreds of billions of dollars.[1] Brands make claims about energy, cognition, immunity, and...

read more
Physiology: The Missing Layer in Precision Medicine

Physiology: The Missing Layer in Precision Medicine

Precision medicine has been positioned as one of the most promising evolutions in modern healthcare. Gene panels. Liquid biopsies. Microbiome-targeted therapies. Multi-omics integration. The premise is compelling: the more precisely we can characterize biological...

read more
Weekly News Roundup | 27 April 2026

Weekly News Roundup | 27 April 2026

Life science news 27 April 2026: Eli Lilly's $7 billion in vivo CAR-T deal, Trump's psychedelics executive order and a first-ever gene therapy for hearing loss headline a landmark week across global life science. Eli Lilly announced on 20 April its acquisition of...

read more
Life Science Daily News: Join the Community

Life Science Daily News: Join the Community

A Community-Driven Hub for Life Sciences News and Discovery In an era of rapid scientific progress and near-constant breakthroughs, having a reliable, inclusive platform to share and explore life-sciences news is more important than ever. Life Science Daily News...

read more
Clinical Trials Roundup | 24 April 2026

Clinical Trials Roundup | 24 April 2026

Neurona Therapeutics' rezanecel demonstrates durable seizure reduction past the one-year mark in drug-resistant mesial temporal lobe epilepsy at the AAN Annual Meeting, Gilead Sciences and Arcus Biosciences' TIGIT inhibitor domvanalimab fails its pivotal Phase 3 lung...

read more

Further News

FDA Accelerated Approval: How the Fast-Track Pathway Works

FDA accelerated approval is one of the agency's most powerful and most debated regulatory tools. Designed to speed access to treatments for patients with serious or life-threatening conditions, it has delivered transformative therapies to those with no other options....

AI Governance in Biopharma Is Failing the Translation Test

Artificial intelligence is no longer experimental in biopharma. It is operational. Across drug discovery and development, AI systems are being used to identify targets, design molecules, optimize mRNA constructs, and simulate biological interactions that were...

Beyond Animal Models: iPSC Assays Unlock the Human Brain

For decades, neurodegenerative research has relied heavily on animal models. While transgenic mice and rats have yielded fundamental insights into the architecture of the central nervous system, they consistently hit a translational roadblock when applied to human...

AI Transparency Gap in SaMD Regulation

Artificial intelligence is no longer on the horizon of medical device regulation — it’s already on regulators’ desks. The FDA’s iterative guidance on AI/ML-based Software as a Medical Device (SaMD), the EU AI Act’s risk classification scheme, and Health Canada’s...

Merck’s $6.7bn Terns Deal: A New Oral CML Treatment

Merck has completed its $6.7 billion acquisition of Terns Pharmaceuticals, gaining control of TERN-701, an investigational oral CML treatment that the pharmaceutical giant hopes will become a cornerstone of its expanding cancer portfolio. The deal, which closed on 5...

IPA Highlights Expansion of Photodynamic Therapy in Türkiye

At the 8th Photodynamic Day of the International Photodynamic Association (IPA) held at Acıbadem University in Istanbul, speakers highlighted continued development of PDT in Türkiye and its growing clinical use internationally. Hosted by Professor Fabienne Dumoulin,...

Medicare GLP-1 Bridge: Weight-Loss Drug Coverage Begins 1st July

Starting, 1 July, millions of Medicare enrollees will gain coverage for weight-loss drugs for the first time, through a temporary pilot programme called the Medicare GLP-1 Bridge. The scheme covers Zepbound, Foundayo and Wegovy at a $50 monthly copayment and marks the...

Self-Care Isn’t Just About Feeling Good. It Helps Us Function Sustainably

Working in healthcare tends to very much not be about self-care, and yet healthcare self-care has never mattered more. It’s about caring for others, prioritising the needs of the many over yourself, and responding both physically and emotionally whilst managing an...

Weekly News Roundup | 29 June 2026

Life science news 29 June 2026: AbbVie and Merck KGaA announce blockbuster acquisitions totalling more than $22 billion, NICE recommends the first disease-modifying therapy for type 1 diabetes for NHS use, and Definium Therapeutics delivers a landmark Phase 3 result...

Why I Founded Mesogen: A New Vision for Personalized Regenerative Medicine

For much of my career I have been fascinated by a simple but profound question: What if medicine could restore what disease destroys? Modern medicine has achieved remarkable success in helping patients manage chronic illnesses. We have developed sophisticated drugs,...

Light-Driven Immune Modulation and Its Impact on Autoimmune Therapy

One of the most consistent epidemiological patterns in multiple sclerosis (MS) is its geographic distribution. Rates rise with distance from the equator, where year-round sunlight exposure is lower.[1] For decades, this has pointed to a role for environmental light in...

Merck KGaA Acquires Bio-Techne for $11.3 Billion in Life Science Tools Deal

The Merck KGaA Bio-Techne acquisition values the Minneapolis-based life science tools company at approximately $11.3 billion. Merck KGaA, the German science and technology group, announced on 25 June 2026 that it will acquire Minneapolis-based Bio-Techne Corporation...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.